New psoriasis drug challenger enters final testing phase
NCT ID NCT07511647
First seen Apr 24, 2026 · Last updated May 15, 2026 · Updated 4 times
Summary
This study tests whether a new drug called QL2106 works as well as the approved drug Tremfya for people with moderate to severe plaque psoriasis. About 318 adults will receive either QL2106 or Tremfya by injection, and doctors will check how much their skin clears up after 16 weeks. The goal is to see if QL2106 is a safe and effective alternative for managing this chronic skin condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLAQUE PSORIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.